Cherney, D.; Folkerts, K.; Mernagh, P.; Nikodem, M.; Pawlitschko, J.; Rossing, P.; Hawkins, N.
Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison. J. Mark. Access Health Policy 2024, 12, 169-180.
https://doi.org/10.3390/jmahp12030014
AMA Style
Cherney D, Folkerts K, Mernagh P, Nikodem M, Pawlitschko J, Rossing P, Hawkins N.
Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison. Journal of Market Access & Health Policy. 2024; 12(3):169-180.
https://doi.org/10.3390/jmahp12030014
Chicago/Turabian Style
Cherney, David, Kerstin Folkerts, Paul Mernagh, Mateusz Nikodem, Joerg Pawlitschko, Peter Rossing, and Neil Hawkins.
2024. "Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison" Journal of Market Access & Health Policy 12, no. 3: 169-180.
https://doi.org/10.3390/jmahp12030014
APA Style
Cherney, D., Folkerts, K., Mernagh, P., Nikodem, M., Pawlitschko, J., Rossing, P., & Hawkins, N.
(2024). Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison. Journal of Market Access & Health Policy, 12(3), 169-180.
https://doi.org/10.3390/jmahp12030014
